A Clinical Trial to Study the Effect of a Drug, Curcumin in Patients With Periodontitis

• Status: Recruiting
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will follow a parallel arm, randomised, double blinded, placebo controlled design.

There will be two groups Group 1 = receiving 1% curcumin chips after routine scaling and root planing (n=20) Group 2 = receiving placebo chips after routine scaling and root planing (n=20) Clinical parameters: ( Baseline, 4 weeks, 12 weeks) Probing pocket depth, clinical attachment level, gingival index, plaque index Cytokine parameter ( Baseline, 4 weeks) Interleukin 1 beta in GCF

Statistical analysis Repeated measures of ANOVA Paired t-tests

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: KLE Society's Institute of Dental Sciences
• Treatments: Curcumin; Iproplatin

Criteria

Inclusion Criteria:

1. Systemically healthy individuals

2. Presence of a minimum of 20 teeth in the oral cavity

3. Localised periodontal pockets with probing depths greater than 4mm i.e., Periodontitis in its stages 2 and 3, as described by the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions, and published by the American Academy of Periodontology (AAP)

Exclusion Criteria:

1. Known allergy to curcumin and/ or hydroxyl propyl methyl cellulose

2. Systemic diseases and/or Inflammatory conditions, Obesity

3. Former or current tobacco users

4. Chronic consumption of alcohol

5. Use of anti-inflammatory drugs and antibiotics over the past 3 months

6. Periodontal therapy in any form, surgical or non surgical in the past 6 months

7. Pregnant and lactating mothers